Risk factors
Neurocrine Biosciences (NBIX) risk factors
Item 1A of every Neurocrine Biosciences Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors47 risks7 new4 dropped18 reworded
The company relies heavily on third-party contract manufacturers for INGREZZA and CRENESSITY without internal manufacturing facilities.
Filed Feb 11, 2026 - FY2024 10-K risk factors44 risks
Commercialization of INGREZZA and new launch of CRENESSITY drive the business and dominate risk factors. Customer concentration with four specialty distributors represents 93% of product sales. Heavy dependence on third-party licenses, collaborations, and contract research organizations.
Filed Feb 10, 2025